Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility for all aesthetics commercial activity including commercial strategy, sales and marketing, branding, loyalty and engagement.
“Given the importance of the DAXXIFY® launch, I’m excited to elevate Erica to the position of Chief Commercial Officer, Aesthetics reporting directly to me. Having worked closely with Erica over the past several months, I have tremendous confidence in her abilities and leadership skills, and she’s been an invaluable partner as we’ve evolved our strategy based on customer feedback. In this role, Erica will not only help us drive the desired DAXXIFY adoption but also help ensure that we continue to grow our RHA® filler business and begin to realize the synergies of our portfolio,” said Mark J. Foley, Chief Executive Officer of Revance. “Erica joined us earlier this year and has a demonstrated track record as a global healthcare leader driving commercial transformation and growth, sales and marketing excellence, flagship product launches and operational efficiencies. Her extensive experience and strong ability to build partnerships both internally and externally, will be invaluable as we seek to maximize the market opportunity of our innovative products.”
“I’ve seen first-hand the tremendous excitement and potential that our product portfolio offers to the aesthetics market,” said Erica Jordan, Chief Commercial Officer, Aesthetics of Revance. “With key launch initiatives underway, I look forward to working with Mark and the rest of the team to continue to elevate Revance and its portfolio of products in the aesthetics marketplace. We will build on our progress, leverage learnings and partner with our current customers to continue to establish the value of DAXXIFY.”
Ms. Jordan joined Revance earlier this year as Senior Vice President of Commercial, bringing 25 years of marketing, sales management, commercial strategy, commercial operations and management experience at leading global healthcare companies. Prior to joining Revance, she served as President of the Metrex division at Envista Holdings, where she developed and executed a successful commercial strategy and implemented operational efficiencies to support double-digital growth. There, she also held the role of Senior Vice President, Sales & Marketing for the Ormco division where she successfully launched multiple new products and enabled significant market share growth for the flagship product categories. Before Envista Holdings, Ms. Jordan served as Vice President, Global Marketing for Change Healthcare where she developed and executed the commercial strategy for the first-ever cloud-based radiology enterprise imaging platform. She has held several marketing, commercial and operational leadership roles at Phillips Healthcare, including her role as Vice President, Senior General Manager, where she built the commercial team and the go-to-market strategy for the newly acquired women’s healthcare business. In addition, she held senior leadership roles at Fujifilm Medical Systems, Siemens Medical Solutions and GE Healthcare.
Ms. Jordan received her B.S. in Marketing and Finance from the University of Wisconsin-Milwaukee and is an active member of the Women Business Leaders of the US Health Care Industry Foundation.
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.
Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.
“Revance”, the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.
Any statements in this press release that are not statements of historical fact, including statements related to our potential to drive DAXXIFY adoption; our market opportunity; the growth potential of the RHA Collection of dermal fillers; our ability to realize the synergies of our portfolio of products; our ability to establish the value of DAXXIFY; the potential to set a new standard of care; the potential benefits of our products; the extent to which our products are considered innovative; the commercialization of DAXXIFY through our Fosun partnership; development of a biosimilar to onabotulinumtoxinA for injection with our partner, Viatris; and our business and marketing strategy, timeline, goals, plans and prospects; constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate to, but are not limited to: our ability to obtain funding for our operations; the timing of capital expenditures; the accuracy of our estimates regarding expenses, revenues, capital requirements, our financial performance and the economics of DAXXIFY and the RHA Collection of dermal fillers; the extent of future impairment charges; our ability to comply with our debt obligations; the impact of macroeconomic factors on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, regulatory meetings, inspections and approvals, clinical trials and other aspects of our business and on the market; our ability to maintain approval of our products; our ability and the ability of our partners to manufacture supplies for DAXXIFY and our drug product candidates; our ability to acquire supplies of the RHA Collection of dermal fillers; the uncertain clinical development process; our ability to obtain, and the timing relating to, regulatory submissions and approvals with respect to our drug product candidates and third-party manufacturers; the risk that clinical trials may not have an effective design or generate positive results or that positive results would assure regulatory approval or commercial success; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, safety, efficacy, commercial acceptance, market, competition and/or size and growth potential of DAXXIFY, the RHA Collection of dermal fillers, and our drug product candidates, if approved; our ability to successfully commercialize DAXXIFY and to continue to successfully commercialize the RHA Collection of dermal fillers; the timing and cost of commercialization activities; securing or maintaining adequate coverage or reimbursement by third-party payers for DAXXIFY; the proper training and administration of our products by physicians and medical staff; our ability to maintain and gain acceptance from injectors in the use of DAXXIFY for aesthetic and therapeutic indications; our ability to expand sales and marketing capabilities; the status of commercial collaborations; our ability to effectively manage the exit of the OPUL payments business; changes in and failures to comply with laws and regulations; our ability to continue obtaining and maintaining intellectual property protection for our products; the cost and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; our ability to limit or mitigate cybersecurity incidents; the volatility of our stock price; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risk Factors" in our Form 10-K filed with the SEC on February 28, 2023, and including, without limitation, our Form 10-Qs for the quarters ended March 31, 2023 and June 30, 2023, filed on May 9, 2023 and August 8, 2023, respectively, and our Form 10-Q for the quarter ended September 30, 2023 expected to be filed November 8, 2023. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108697331/en/
Source: Revance Therapeutics, Inc.
View this news release online at: